Aug 11 (Reuters) - British drugmaker GSK said on
Monday its supplemental new drug application for antibiotic drug
gepotidacin has been accepted for priority review by the U.S.
Food and Drug Administration for the oral treatment of
uncomplicated urogenital gonorrhoea.